# US 6,726,930 B1 · Sustained release heterodisperse hydrogel systems for insoluble drugs

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,726,930 B1
- Document ID: US6726930B1
- Status: Granted
- Kind: B1
- Application number: 09/654,691
- Filed: 2000-09-05
- Granted: 2004-04-27
- Earliest claimed: 1993-09-09
- Assignees: Penwest Pharmaceuticals Co.
- Inventors: Anand R. Baichwal
- Web page: https://patentgrep.com/patent/US6726930B1

## CPC

- A61K 9/1611: {Inorganic compounds}
- A61K 9/1623: {Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules}
- A61K 9/1652: {Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin (homeopathic globules A61K9/1623)}
- A61K 9/2009: {Inorganic compounds}
- A61K 9/205: {Polysaccharides, e.g. alginate, gums; Cyclodextrin}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/2077: {Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets}
- A61K 9/2866: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A sustained release pharmaceutical formulation includes a sustained release excipient including a gelling agent, an inert pharmaceutical diluent, an optional cationic cross-linking agent, and a medicament having moderate to poor solubility is disclosed. In certain embodiments, the sustained release excipient is granulated with a solution or suspension of a hydrophobic polymer in an amount effective to slow the hydration of the gelling agent when the formulation is exposed to an environmental fluid. In another embodiment, the tablet is coated with a hydrophobic polymer.

## Claims

### Claim 1

A sustained release oral solid dosage form for providing an effective dose of a medicament having a solubility of less than about 10 g/l over a 24 hour period, comprising
an effective amount of a medicament to render a therapeutic effect;
a gelling agent comprising xanthan gum and locust bean gum in a ratio from about 1:3 to about 3:1;
a pharmaceutically acceptable cationic cross-linking agent capable of cross-linking with said gelling agent and increasing the gel strength when the dosage form is exposed to an environmental fluid; and
an inert pharmaceutical diluent, the ratio of said inert diluent to the total amount of said xanthan gum and said locust bean gum being from about 1:8 to about 8:1;
wherein said dosage form is a tablet.

### Claim 2 (depends on 1)

The dosage form of claim 1, wherein a hydrophobic material selected from the group consisting of an alkylcellulose, a hydrophobic cellulosic material, a copolymer of acrylic and methacrylic acid esters, hydrogenated vegetable oils, shellac, waxes, zein and mixtures of any of the foregoing is admixed with the medicament, the xanthan and locust bean gum, the inert diluent and the cationic cross-linking agent.

### Claim 3 (depends on 1)

The dosage form of claim 1, wherein said medicament is selected from the group consisting of nifedipine, nimodipine, nivadipine, nitrendipine, nisolidipine, niludipine, nicardipine and felodipine.

### Claim 4 (depends on 1)

The dosage form of claim 1, wherein said medicament is nifedipine.

### Claim 5 (depends on 4)

The dosage form of claim 4, wherein the amount of nifedipine is 20 mg, 30 mg, 60 mg or 90 mg.

### Claim 6 (depends on 1)

The dosage form of claim 1, wherein said cationic cross-linking agent comprises an alkali metal or an alkaline earth metal sulfate, chloride, borate, bromide, citrate, acetate, or lactate.

### Claim 7 (depends on 1)

The dosage form of claim 1, wherein said cationic cross-linking agent comprises calcium sulfate.

### Claim 8 (depends on 1)

The sustained release oral solid dosage form of claim 1, wherein said medicament is a dihydropyridine.

### Claim 9

A sustained release oral solid dosage form for providing an effective dose of a medicament having a solubility of less than about 10 g/l over a 24 hour period, comprising
an effective amount of a medicament to render a therapeutic effect;
a gelling agent comprising xanthan gum and locust bean gum in a ratio from about 1:3 to about 3:1;
a pharmaceutically acceptable cationic cross-linking agent capable of cross-linking with said gelling agent and increasing the gel strength when the dosage form is exposed to an environmental fluid; and
an inert pharmaceutical diluent, the ratio of said inert diluent to the total amount of said xanthan gum and said locust bean gum being from about 1:8 to about 8:1;
wherein said dosage form is a tablet coated with a hydrophobic coating to a weight gain from about 1 to about 20 percent of the total weight of said tablet.

### Claim 10 (depends on 9)

The sustained release oral solid dosage form of claim 9, wherein a hydrophobic material selected from the group consisting of an alkylcellulose, a hydrophobic cellulosic material, a copolymer of acrylic and methacrylic acid esters, hydrogenated vegetable oils, shellac, waxes, zein and mixtures of any of the foregoing is admixed with the medicament, the xanthan gum and locust bean gum, the inert diluent and the cationic cross-linking agent.

### Claim 11 (depends on 9)

The sustained release oral solid dosage form of claim 9, wherein said medicament is a dihydropyridine.

### Claim 12 (depends on 9)

The sustained release oral solid dosage form of claim 9, wherein said medicament is selected from the group consisting of nifedipine, nimodipine, hivadipine, nitrendipine, nisolidipine, niludipine, nicardipine and felodipine.

### Claim 13 (depends on 9)

The sustained release oral solid dosage form of claim 9, wherein said medicament is nifedipine.

### Claim 14 (depends on 13)

The sustained release oral solid dosage form of claim 13, wherein the amount of nifedipine is 20 mg, 30 mg, 60 mg, or 90 mg.

### Claim 15 (depends on 9)

The sustained release oral solid dosage form of claim 9, wherein said cationic cross-linking agent comprises an alkali metal or an alkaline earth metal sulfate, chloride, borate, bromide, citrate, acetate, or lactate.

### Claim 16 (depends on 9)

The sustained release oral solid dosage form of claim 9, wherein said cationic cross-linking agent comprises calcium sulfate.
